ALS

Classic ALS involves neurons in the brain and spinal cord ([[upper motor neuron | image = ALS Affected neurons and muscles.png | caption = Parts of the nervous system affected by ALS, causing progressive symptoms in skeletal muscles throughout the body | field = Neurology | symptoms = Early: Stiff muscles, muscle twitches, gradual increasing weakness
Later: Difficulty in speaking, swallowing, and breathing; respiratory failure 10–15% experience frontotemporal dementia | complications = Falling (accident); Respiratory failure; Pneumonia; Malnutrition | onset = 45–75 years | duration = | causes = Unknown (about 85%), genetic (about 15%) | risks = Genetic risk factors; age; male sex; heavy metals; organic chemicals; smoking; electric shock; physical exercise; head injury | diagnosis = Clinical diagnosis of exclusion based on progressive symptoms of upper and lower motor neuron degeneration in which no other explanation can be found. Supportive evidence from electromyography, genetic testing, and neuroimaging | differential = Multifocal motor neuropathy, Kennedy's disease, Hereditary spastic paraplegia, Nerve compression syndrome, Diabetic neuropathy, Post-polio syndrome, Myasthenia gravis, Multiple sclerosis | prevention = | treatment = Walker (mobility); Wheelchair; Non-invasive ventilation; Feeding tube; Augmentative and alternative communication; symptomatic management | medication = Riluzole, Edaravone, Sodium phenylbutyrate/ursodoxicoltaurine, Tofersen, Dextromethorphan/quinidine | prognosis = Life expectancy highly variable but typically 2–4 years after diagnosis | frequency = }} | deaths = | alt = Diagram of a human nervous system highlighting the brain, spinal cord, motor neurons, and muscles of the body affected by ALS }}

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or '''Lou Gehrig's disease''' in the United States, is a rare and terminal neurodegenerative disease that results in the progressive loss of motor neurons that control voluntary muscles. ALS is the most common form of the motor neuron diseases. Early symptoms of ALS include stiff muscles, muscle twitches, gradual increasing weakness, and muscle wasting. ''Limb-onset ALS'' begins with weakness in the arms or legs, while ''bulbar-onset ALS'' begins with difficulty in speaking or swallowing. Around half of people with ALS develop at least mild difficulties with thinking and behavior, and about 15% develop frontotemporal dementia. Motor neuron loss continues until the abilities to eat, speak, move, or, lastly, breathe are lost.

Most cases of ALS (about 90% to 95%) have no known cause, and are known as ''sporadic ALS''. However, both genetic and environmental factors are believed to be involved. The remaining 5% to 10% of cases have a genetic cause, often linked to a history of the disease in the family, and these are known as ''familial ALS'' (hereditary). About half of these genetic cases are due to disease-causing variants in one of four specific genes. The diagnosis is based on a person's signs and symptoms, with testing conducted to rule out other potential causes.

There is no known cure for ALS. The goal of treatment is to slow the disease progression, and improve symptoms. Treatments that slow ALS include riluzole (extends life by two to three months) and sodium phenylbutyrate/ursodoxicoltaurine (extends life by around seven months). Non-invasive ventilation may result in both improved quality, and length of life. Mechanical ventilation can prolong survival but does not stop disease progression. A feeding tube may help maintain weight and nutrition. Death is usually caused by respiratory failure. The disease can affect people of any age, but usually starts around the age of 60. The average survival from onset to death is two to four years, though this can vary, and about 10% of those affected survive longer than ten years.

Descriptions of the disease date back to at least 1824 by Charles Bell. In 1869, the connection between the symptoms and the underlying neurological problems was first described by French neurologist Jean-Martin Charcot, who in 1874 began using the term ''amyotrophic lateral sclerosis''. Provided by Wikipedia
1
Affiche uitgegeven in 2000 door de Aktief Linkse Studenten (ALS, Gent) voor een vergadering. Afbeelding: tekening in zwart-wit van de ...

Full description

By ALS
Date 2000
affiche
2
Archiefcollectie Museale collectie Bibliotheekcollectie
3
Affiche uitgegeven in 1990-1991 door de Aktief Linkse Studenten (ALS) Antwerpen tegen de Golfoorlog. Afbeelding: verbodsbord met mijnenjager. Tekst: Geen ...

Full description

By ALS, De Bruyn, Erik
Date 1990-1991
affiche
5
Date [s.a.]
...Aktief Linkse Studenten (ALS)...
monografie
6
Deze publicatie bevat volgende liederen :
De Internationale (Vlaams)
La International (Spaans)
The International (Engels)
L'Internationale (Frans)
Lied van Geen taal
Socialisten-Marsch
Solidariteit
Le Drapeau Rouge
La Marseillaise Anti-Clérique
We ...

Full description

...Aktief Linkse Studenten (ALS)...
bladmuziek
7
Date 1977-1978
...Aktief Linkse Studenten (ALS)...
periodiek
8
Date 1990
...Aktief Linkse Studenten (ALS)...
periodiek
9
Periodiciteit: tweewekelijks Date 1978
...Aktief Linkse Studenten (ALS)...
periodiek
10
Date 1976-1984
...Aktief Linkse Studenten (ALS)...
periodiek
11
12
13
Date 1985
...Aktief Linkse Studenten (ALS)...
brochure